Straits Times Index
3,144.76 -38.85 (-1.22%) S&P 500
5,058.23 -3.59 (-0.07%) Dow
37,825.79 +90.68 (+0.24%) Nasdaq
15,888.67 +3.66 (+0.02%) Bitcoin USD
62,775.48 -978.13 (-1.53%) CMC Crypto 200
885.54 0.00 (0.00%)
LLY Jan 2025 380.000 put
| Previous close | 2.0300 |
| Open | 2.0300 |
| Bid | 0.5800 |
| Ask | 5.8500 |
| Strike | 380.00 |
| Expiry date | 2025-01-17 |
| Day's range | 1.6400 - 2.0300 |
| Contract range | N/A |
| Volume | |
| Open interest | 116 |
PR NewswireLilly Confirms Date and Conference Call for First-Quarter 2024 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2024 financial results on April 30, 2024. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.
Insider MonkeyJim Cramer is Recommending These 10 Stocks in April
In this article, we will take a detailed look at Jim Cramer is Recommending These 10 Stocks in April. For a quick overview of such stocks, read our article Jim Cramer is Recommending These 5 Stocks in April. Jim Cramer has been sharing his thoughts about the latest market pullback on his programs on CNBC. Last week, Cramer said […]
- Reuters
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm
The cybersecurity firm BrandShield has taken down more than 250 websites selling fake versions of popular weight-loss and diabetes drugs in the GLP-1 class, the company’s CEO Yoav Keren told Reuters. BrandShield, which shared this information exclusively with Reuters, said that out of the 279 pharmacy websites the company closed last year for selling drugs intended to treat metabolic conditions, more than 90% were related to GLP-1 medicines, according to Keren. Novo Nordisk’s Ozempic and Wegovy and Eli Lilly’s Mounjaro and Zepbound are GLP-1 drugs, which were developed for type 2 diabetes but also reduce food cravings and cause the stomach to empty more slowly.
